Brokerages Set Masimo Co. (NASDAQ:MASI) Price Target at $145.33

Masimo Co. (NASDAQ:MASI) has been assigned an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $145.33.

MASI has been the subject of a number of research analyst reports. Piper Sandler reissued an “overweight” rating on shares of Masimo in a report on Friday. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Friday, September 20th. Finally, BTIG Research lifted their price objective on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th.

Masimo Stock Down 0.2 %

Shares of NASDAQ:MASI opened at $143.73 on Friday. The stock has a market capitalization of $7.64 billion, a price-to-earnings ratio of 97.78 and a beta of 0.99. The stock has a fifty day simple moving average of $126.30 and a two-hundred day simple moving average of $125.07. Masimo has a 12-month low of $75.36 and a 12-month high of $153.93. The company has a current ratio of 2.09, a quick ratio of 1.15 and a debt-to-equity ratio of 0.55.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. The business had revenue of $496.30 million during the quarter, compared to analyst estimates of $493.92 million. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.62 EPS. On average, research analysts anticipate that Masimo will post 3.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Masimo

A number of hedge funds have recently made changes to their positions in MASI. Riverview Trust Co purchased a new stake in shares of Masimo in the first quarter worth about $25,000. NBC Securities Inc. lifted its position in shares of Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 73 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 111 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 200 shares in the last quarter. Finally, HHM Wealth Advisors LLC lifted its position in shares of Masimo by 25.0% in the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after buying an additional 125 shares in the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.